Multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) are the most common atypical parkinsonisms. These disorders are characterized by varying combinations of autonomic, cerebellar and pyramidal system, and cognitive dysfunctions. In this paper, we reviewed the evidence available on the presence and type of neuropsychiatric disturbances in MSA, PSP, and CBD. A MedLine, Excerpta Medica, PsycLit, PsycInfo, and Index Medicus search was performed to identify all articles published on this topic between 1965 and 2018. Neuropsychiatric disturbances including depression, anxiety, agitation, and behavioral abnormalities have been frequently described in these disorders, with depression as the most frequent disturbance. MSA patients show a higher frequency of depressive disorders when compared to healthy controls. An increased frequency of anxiety disorders has also been reported in some patients, and no studies have investigated apathy. PSP patients may have depression, apathy, disinhibition, and to a lesser extent, anxiety and agitation. In CBD, neuropsychiatric disorders are similar to those present in PSP. Hallucinations and delusions are rarely reported in these disorders. Neuropsychiatric symptoms in MSA, PSP, and CBD do not appear to be related to the severity of motor dysfunction and are one of the main factors that determine a low quality of life. The results suggest that neuropsychiatric disturbances should always be assessed in patients with atypical parkinsonisms.

Neuropsychiatric disturbances in atypical Parkinsonian disorders / Belvisi, Daniele; Berardelli, Isabella; Suppa, Antonio; Fabbrini, Andrea; Pasquini, Massimo; Pompili, Maurizio; Fabbrini, Giovanni. - In: NEUROPSYCHIATRIC DISEASE AND TREATMENT. - ISSN 1176-6328. - 14:(2018), pp. 2643-2656. [10.2147/NDT.S178263]

Neuropsychiatric disturbances in atypical Parkinsonian disorders

Belvisi, Daniele;Berardelli, Isabella;Suppa, Antonio;Fabbrini, Andrea;Pasquini, Massimo;Pompili, Maurizio;Fabbrini, Giovanni
2018

Abstract

Multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) are the most common atypical parkinsonisms. These disorders are characterized by varying combinations of autonomic, cerebellar and pyramidal system, and cognitive dysfunctions. In this paper, we reviewed the evidence available on the presence and type of neuropsychiatric disturbances in MSA, PSP, and CBD. A MedLine, Excerpta Medica, PsycLit, PsycInfo, and Index Medicus search was performed to identify all articles published on this topic between 1965 and 2018. Neuropsychiatric disturbances including depression, anxiety, agitation, and behavioral abnormalities have been frequently described in these disorders, with depression as the most frequent disturbance. MSA patients show a higher frequency of depressive disorders when compared to healthy controls. An increased frequency of anxiety disorders has also been reported in some patients, and no studies have investigated apathy. PSP patients may have depression, apathy, disinhibition, and to a lesser extent, anxiety and agitation. In CBD, neuropsychiatric disorders are similar to those present in PSP. Hallucinations and delusions are rarely reported in these disorders. Neuropsychiatric symptoms in MSA, PSP, and CBD do not appear to be related to the severity of motor dysfunction and are one of the main factors that determine a low quality of life. The results suggest that neuropsychiatric disturbances should always be assessed in patients with atypical parkinsonisms.
2018
Atypical parkinsonisms; corticobasal degeneration; depression; multiple system atrophy; neuropsychiatric disturbances; progressive supranuclear palsy; psychiatry and mental health; biological psychiatry
01 Pubblicazione su rivista::01a Articolo in rivista
Neuropsychiatric disturbances in atypical Parkinsonian disorders / Belvisi, Daniele; Berardelli, Isabella; Suppa, Antonio; Fabbrini, Andrea; Pasquini, Massimo; Pompili, Maurizio; Fabbrini, Giovanni. - In: NEUROPSYCHIATRIC DISEASE AND TREATMENT. - ISSN 1176-6328. - 14:(2018), pp. 2643-2656. [10.2147/NDT.S178263]
File allegati a questo prodotto
File Dimensione Formato  
Belvisi_Neuropsychiatric_2018.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 630.05 kB
Formato Adobe PDF
630.05 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1205392
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 23
social impact